Not sure if this highly thorough review of CCR5 and Breast Cancer from September 8, 2023 Cell publication has hit this board; Richard Pestell is one of the co-authors. Leronlimab’s Carboplatin 1b/2 combo results are discussed along the way. You can not read this and fail to conclude Leronlimab will have a significant role to play with a sub-set of cancers. The FDA dropped the ball when presented with truly breakthrough designation results. The scientific R&D bench of major BP companies are either asleep at the switch or their legal department has worked through a NDA. This diamond must be allowed to shine at some point, for the good of humanity.

https://www.mdpi.com/2073-4409/12/18/2237